H.C. Wainwright starts Kyverna at neutral, says awaiting more data (NASDAQ:KYTX)
2024-07-03
duoogle H.C. Wainwright initiated coverage of Kyverna Therapeutics (NASDAQ:KYTX) with a neutral rating, stating that it was awaiting more data on the company’s cell therapy KYV-101 before becoming more positive on the stock. The investment bank noted that the company recently shared “lackluster” data on KYV-101 in the treatment ofContinue Reading